TVTX

Travere Therapeutics Inc

52.30

Oct 20 • 3:59 PM ET +1.81 (3.58%)

50.00

Aftermarket • 5:15 PM ET -2.30 (-4.40%)

Healthcare Biotechnology USA Mid NASD

Peers: VERA VRTX MAZE MIRM PTCT ARDX BMRN RYTM NVS AKBA

| Held by: VTI XBI IWM VXF VB IWO IBB VBK VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	4.93B
Enterprise Value	5.06B
Income	-67.68M
Sales	591.33M
Book/sh	0.26
Cash/sh	5.19
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	497
IPO	Oct 06, 2003

P/E	-
Forward P/E	16.92
PEG	-
P/S	8.34
P/B	200.85
P/C	10.08
P/FCF	53.04
EV/EBITDA	220.76
EV/Sales	8.55
Quick Ratio	3.99
Current Ratio	4.05
Debt/Eq	25.16
LT Debt/Eq	24.91
Option/Short	Yes / Yes

EPS (ttm)	-0.76
EPS next Y	3.09
EPS next Q	-0.07
EPS this Y	45.76%
EPS next Y	2065.43%
EPS next 5Y	-
EPS past 3/5Y	49.47% 30.85%
Sales past 3/5Y	64.89% 19.87%
EPS Y/Y TTM	64.40%
Sales Y/Y TTM	77.12%
EPS Q/Q	-159.55%
Sales Q/Q	48.17%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	-174.68% 7.83%

Insider Own	2.96%
Insider Trans	-33.88%
Inst Own	114.35%
Inst Trans	4.61%
ROA	-9.99%
ROE	-236.35%
ROIC	-10.65%
Gross Margin	87.89%
Oper. Margin	-6.84%
Profit Margin	-11.45%
SMA20	-5.56%
SMA50	-14.24%
SMA200	13.84%
Trades

Shs Outstand	94.17M
Shs Float	91.48M
Short Float	13.83%
Short Ratio	7.75
Short Interest	12.66M
52W High	68.73 -23.91%
52W Low	22.59 131.52%
Volatility	4.48% 4.19%
ATR (14)	2.36
RSI (14)	37.80
Beta	1.10
Rel Volume	1.26
Avg Volume	1.63M
Volume	2,057,450

Perf Week	0.97%
Perf Month	-16.80%
Perf Quarter	-7.04%
Perf Half Y	34.86%
Perf YTD	36.88%
Perf Year	87.52%
Perf 3Y	623.37%
Perf 5Y	111.23%
Perf 10Y	156.25%
Recom	1.13
Target Price	75.21
Prev Close	50.49
Price	52.30
Change %	3.58%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight	$49
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30

Show Previous Ratings

Oct-12-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-02-26 10:00AM	Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026 (Business Wire)
Sep-23-26 07:00AM	Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in Focal Segmental Glomerulosclerosis (Business Wire)
Sep-21-26 04:05PM	Travere Therapeutics Announces Planned Chief Executive Officer Transition (Business Wire)
Sep-17-26 04:30PM	Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum (Business Wire)
05:00PM	Loading…
Sep-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-26 03:45PM	Travere Therapeutics Outlook Brightens As Turnaround Looms (Investor's Business Daily)
Aug-24-26 09:28AM	Guardant Health Dives After Losing A Patent Dispute; Judge Orders Royalties (Investor's Business Daily)
Aug-21-26 01:11PM	IBD Stock Of The Day, Travere Therapeutics, Tests Another Breakout. Can The Stock Get Any 'Sweeter?' (Investor's Business Daily)
Aug-12-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-06-26 08:30AM	Travere Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
Aug-05-26 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire) +12.03%
01:05AM	Travere Therapeutics Inc (TVTX) (Q2 2026) Earnings Call Highlights: Record FILSPARI Demand and ... (GuruFocus.com)
Aug-04-26 04:09PM	Travere: Q2 Earnings Snapshot (Associated Press)
04:01PM	Travere Therapeutics Reports Second Quarter 2026 Financial Results (Business Wire)
04:30PM	Loading…
Jul-28-26 04:30PM	Travere Therapeutics to Report Second Quarter 2026 Financial Results (Business Wire)
Jul-10-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-16-26 04:30PM	Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027 (Business Wire)
Jun-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.40%
Jun-04-26 10:09AM	Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress (Business Wire)
Jun-02-26 02:14PM	TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside (Stocktwits)
07:01AM	Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases (Business Wire)
May-27-26 04:05PM	Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in IgA Nephropathy (Business Wire) +7.83%
May-21-26 12:54PM	Travere, IBD Stock Of The Day, Is On Path To $3 Billion And In A Buy Zone (Investor's Business Daily)
May-12-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-26 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-06-26 10:28PM	Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes (Business Wire)
May-05-26 04:01PM	Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes (Business Wire)
May-04-26 08:26PM	Travere Therapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
04:06PM	Travere: Q1 Earnings Snapshot (Associated Press)
04:01PM	Loading…
04:01PM	Travere Therapeutics Reports First Quarter 2026 Financial Results (Business Wire)
Apr-27-26 04:30PM	Travere Therapeutics to Report First Quarter 2026 Financial Results (Business Wire)
Apr-17-26 12:16PM	Four Biotech Stocks Near Buy Points As Earnings Season Kicks In (Investor's Business Daily)
Apr-14-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +37.23%
02:06PM	FDA approves first drug for rare kidney scarring disease (Quartz)
09:05AM	Travere Therapeutics Stock Skyrockets On FDA Approval (Investor's Business Daily)
08:07AM	Travere wins long-awaited approval for kidney disease drug (BioPharma Dive)
07:04AM	Travere Therapeutics gains FDA approval for sparsentan in FSGS (Pharmaceutical Business Review)
Apr-13-26 06:16PM	Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS (Business Wire) +6.01%
Mar-10-26 12:14PM	VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study (Zacks)
08:02AM	Piper Sandler Increases Target Price for Travere Therapeutics (TVTX) (Insider Monkey)
Feb-24-26 10:18AM	Travere Therapeutics, Inc. (TVTX): A Bull Case Theory (Insider Monkey)
06:50AM	Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 (Insider Monkey)
Feb-20-26 08:30AM	Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
12:03AM	Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-19-26 11:08PM	Travere Therapeutics Q4 Earnings Call Highlights (MarketBeat) +5.13%
05:30PM	Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates (Zacks)
05:00PM	Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss (Investing.com)
04:15PM	Travere: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-18-26 01:10AM	Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market (Insider Monkey)
Feb-17-26 10:00AM	Kiniksa Pharmaceuticals International, plc (KNSA) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-15-26 05:03PM	Travere Therapeutics Targets April FSGS FILSPARI Decision as IgAN Sales Accelerate, HCU Trial Restarts (MarketBeat)
Feb-12-26 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -9.08%
10:00AM	Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-04-26 04:30PM	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit (Business Wire) -6.98%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.65%
Jan-22-26 09:52PM	BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari (Insider Monkey) +5.24%
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
06:44AM	Travere Stock Slips After FDA Delays Review Of Key Kidney Drug (Benzinga)
Jan-13-26 07:51PM	Why Travere Therapeutics Stock Got Trounced on Tuesday (Motley Fool) -14.63%
04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily)
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
01:24PM	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire)
11:19AM	Options Bears Eye Plummeting Biotech Stock (Schaeffer's Research)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
09:54AM	Travere Therapeutics Hammered On A Potential, Surprise Delay For Filspari (Investor's Business Daily)
Jan-12-26 05:00PM	Travere Therapeutics Provides Corporate Update and 2026 Outlook (Business Wire)
Jan-05-26 04:30PM	Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.06%
Dec-25-25 10:44AM	Dow Jones, S&P 500 Hit Record Highs. Stock Market Closed For Christmas. (Investor's Business Daily)
Dec-24-25 06:51PM	Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday (Motley Fool) +13.91%
04:40PM	Nvidia Buying AI Chip Startup Groq In Record $20 Billion Deal: CNBC (Investor's Business Daily)
01:40PM	Dow Jones, S&P 500 Hit Record Highs Heading Into Christmas Holiday (Investor's Business Daily)
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 15 '26	Option Exercise	12.15	243,735	2,961,597	676,621	Oct 19 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 15 '26	Sale	53.82	243,735	13,116,671	432,886	Oct 19 04:05 PM
ERIC DUBE	Director	Oct 15 '26	Proposed Sale	53.27	243,735	12,983,763		Oct 15 04:40 PM
ROTE WILLIAM E.	Chief Research Officer	Sep 16 '26	Option Exercise	21.29	112,850	2,402,186	211,047	Sep 17 09:35 PM
ROTE WILLIAM E.	Chief Research Officer	Sep 15 '26	Option Exercise	21.57	78,650	1,696,864	194,395	Sep 17 09:35 PM
ROTE WILLIAM E.	Chief Research Officer	Sep 16 '26	Sale	63.33	112,850	7,146,644	98,197	Sep 17 09:35 PM
ROTE WILLIAM E.	Chief Research Officer	Sep 15 '26	Sale	62.25	96,198	5,988,753	98,197	Sep 17 09:35 PM
Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sep 16 '26	Option Exercise	14.19	172,717	2,451,533	289,783	Sep 17 09:35 PM
Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sep 15 '26	Option Exercise	18.31	77,190	1,413,039	219,256	Sep 17 09:35 PM
Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sep 17 '26	Option Exercise	22.40	8,282	185,517	125,348	Sep 17 09:35 PM
Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sep 16 '26	Sale	63.43	172,717	10,956,088	117,066	Sep 17 09:35 PM
Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sep 15 '26	Sale	62.26	102,190	6,362,825	117,066	Sep 17 09:35 PM
Heerma Peter	EVP, CHIEF COMMERCIAL OFFICER	Sep 17 '26	Sale	65.07	8,282	538,917	117,066	Sep 17 09:35 PM
Inrig Jula	EVP, Head of R&D & CMO	Sep 15 '26	Option Exercise	8.93	32,395	289,287	145,165	Sep 17 09:33 PM
Inrig Jula	EVP, Head of R&D & CMO	Sep 15 '26	Sale	62.34	44,674	2,785,021	100,491	Sep 17 09:33 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 15 '26	Option Exercise	15.46	37,500	579,750	142,889	Sep 17 09:32 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 15 '26	Sale	62.34	37,500	2,337,695	105,389	Sep 17 09:32 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 16 '26	Option Exercise	23.34	195,841	4,570,929	628,727	Sep 17 09:31 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 17 '26	Option Exercise	23.34	108,493	2,532,227	541,379	Sep 17 09:31 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 15 '26	Option Exercise	23.34	95,666	2,232,844	528,552	Sep 17 09:31 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 16 '26	Sale	63.45	195,841	12,425,254	432,886	Sep 17 09:31 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 17 '26	Sale	64.61	108,493	7,009,671	432,886	Sep 17 09:31 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Sep 15 '26	Sale	62.26	95,666	5,955,804	432,886	Sep 17 09:31 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 15 '26	Option Exercise	17.44	20,000	348,800	138,016	Sep 17 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 15 '26	Sale	62.34	50,508	3,148,544	87,508	Sep 17 09:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Sep 15 '26	Option Exercise	24.19	5,375	129,998	47,728	Sep 17 09:29 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Sep 15 '26	Sale	62.33	5,375	335,005	42,353	Sep 17 09:29 PM
ERIC DUBE	Director	Sep 17 '26	Proposed Sale	63.48	108,493	6,887,136		Sep 17 04:35 PM
PETER HEERMA	Officer	Sep 17 '26	Proposed Sale	63.48	8,282	525,741		Sep 17 04:30 PM
WILLIAM ROTE	Officer	Sep 16 '26	Proposed Sale	62.51	112,850	7,054,254		Sep 16 04:33 PM
PETER HEERMA	Officer	Sep 16 '26	Proposed Sale	62.51	172,717	10,796,540		Sep 16 04:32 PM
ERIC DUBE	Director	Sep 16 '26	Proposed Sale	62.51	195,841	12,242,021		Sep 16 04:30 PM
SANDRA CALVIN	Officer	Sep 15 '26	Proposed Sale	65.79	5,375	353,621		Sep 15 04:44 PM
CHRISTOPHER CLINE	Officer	Sep 15 '26	Proposed Sale	65.79	50,508	3,322,921		Sep 15 04:44 PM
ELIZABETH REED	Officer	Sep 15 '26	Proposed Sale	65.79	39,576	2,603,705		Sep 15 04:43 PM
ERIC DUBE	Director	Sep 15 '26	Proposed Sale	65.79	95,666	6,293,866		Sep 15 04:42 PM
PETER HEERMA	Officer	Sep 15 '26	Proposed Sale	65.79	102,190	6,723,080		Sep 15 04:41 PM
WILLIAM ROTE	Officer	Sep 15 '26	Proposed Sale	65.79	96,198	6,328,866		Sep 15 04:35 PM
JULA INRIG	Officer	Sep 15 '26	Proposed Sale	65.79	44,674	2,939,102		Sep 15 04:24 PM
Meckler Jeffrey A	Director	Sep 10 '26	Option Exercise	21.98	20,000	439,600	111,500	Sep 11 04:05 PM
Meckler Jeffrey A	Director	Sep 10 '26	Sale	67.31	20,000	1,346,106	91,500	Sep 11 04:05 PM
JEFFREY MECKLER	Director	Sep 10 '26	Proposed Sale	66.22	20,000	1,324,400		Sep 10 04:38 PM
LYONS GARY A	Director	Aug 17 '26	Option Exercise	17.44	5,000	87,200	66,500	Aug 19 04:05 PM
LYONS GARY A	Director	Aug 18 '26	Option Exercise	17.44	5,000	87,200	66,500	Aug 19 04:05 PM
LYONS GARY A	Director	Aug 18 '26	Sale	63.37	5,000	316,860	61,500	Aug 19 04:05 PM
LYONS GARY A	Director	Aug 17 '26	Sale	63.20	5,000	315,986	61,500	Aug 19 04:05 PM
GARY LYONS	Director	Aug 18 '26	Proposed Sale	63.53	5,000	317,650		Aug 18 04:24 PM
GARY A LYONS	Director	Aug 17 '26	Proposed Sale	62.14	5,000	310,700		Aug 17 04:31 PM
Coughlin Timothy	Director	Jun 12 '26	Option Exercise	26.52	10,000	265,200	66,250	Jun 16 04:46 PM
Coughlin Timothy	Director	Jun 12 '26	Sale	50.07	10,000	500,747	56,250	Jun 16 04:46 PM
Baynes Roy D.	Director	Jun 12 '26	Option Exercise	21.38	4,500	96,210	46,000	Jun 16 04:42 PM
Baynes Roy D.	Director	Jun 12 '26	Sale	50.00	4,500	225,000	41,500	Jun 16 04:42 PM
ROY BAYNES	Director	Jun 12 '26	Proposed Sale	50.00	4,500	225,000		Jun 12 04:05 PM
Coughlin Timothy	Director	Jun 12 '26	Proposed Sale	50.04	10,000	500,430		Jun 12 12:20 PM
Coughlin Timothy	Director	May 15 '26	Sale	43.49	3,250	141,342	52,250	May 19 04:05 PM
Coughlin Timothy	Director	May 15 '26	Proposed Sale	43.44	3,250	141,183		May 15 12:51 PM
Baynes Roy D.	Director	May 05 '26	Option Exercise	18.27	4,500	82,215	42,000	May 06 08:00 PM
Baynes Roy D.	Director	May 05 '26	Sale	46.65	4,500	209,925	37,500	May 06 08:00 PM
Meckler Jeffrey A	Director	May 04 '26	Option Exercise	16.33	8,000	130,640	95,500	May 06 08:00 PM
Meckler Jeffrey A	Director	May 04 '26	Sale	45.00	8,000	360,000	87,500	May 06 08:00 PM
ROTE WILLIAM E.	Chief Research Officer	May 04 '26	Option Exercise	0.00	4,250	0	118,237	May 06 08:00 PM
ROTE WILLIAM E.	Chief Research Officer	May 06 '26	Sale	43.95	2,763	121,434	115,474	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 04 '26	Option Exercise	14.81	24,250	359,200	125,211	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 04 '26	Sale	45.00	20,000	900,000	105,211	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '26	Sale	46.65	2,174	101,417	107,287	May 06 08:00 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 06 '26	Sale	43.95	2,076	91,240	105,211	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 04 '26	Option Exercise	18.47	24,250	448,000	131,473	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 04 '26	Sale	45.00	20,000	900,000	111,473	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 05 '26	Sale	46.65	2,174	101,417	113,549	May 06 08:00 PM
Inrig Jula	CHIEF MEDICAL OFFICER	May 06 '26	Sale	43.95	311	13,668	113,238	May 06 08:00 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 04 '26	Option Exercise	0.00	4,250	0	142,858	May 06 08:00 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '26	Sale	46.65	2,174	101,417	140,684	May 06 08:00 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 04 '26	Option Exercise	0.00	22,500	0	455,386	May 06 08:00 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 06 '26	Sale	43.95	22,500	988,875	432,886	May 06 08:00 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 04 '26	Option Exercise	0.00	4,250	0	121,149	May 06 08:00 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '26	Sale	46.65	2,181	101,744	118,968	May 06 08:00 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 06 '26	Sale	43.95	310	13,624	118,658	May 06 08:00 PM
CHRISTOPHER CLINE	Officer	May 06 '26	Proposed Sale	43.95	310	13,624		May 06 04:03 PM
ELIZABETH REED	Officer	May 06 '26	Proposed Sale	43.95	2,076	91,240		May 06 04:03 PM
JULA INRIG	Officer	May 06 '26	Proposed Sale	43.95	311	13,668		May 06 04:02 PM
Dube Eric M	Officer	May 06 '26	Proposed Sale	43.95	22,500	988,875		May 06 09:55 AM
ROTE WILLIAM E.	Officer	May 06 '26	Proposed Sale	43.95	2,763	121,434		May 06 09:37 AM
Christopher Cline	Officer	May 05 '26	Proposed Sale	46.65	2,181	101,744		May 05 07:48 PM
Elizabeth E. Reed	Officer	May 05 '26	Proposed Sale	46.65	2,174	101,417		May 05 07:32 PM
Jula Inrig	Officer	May 05 '26	Proposed Sale	46.65	2,174	101,417		May 05 07:31 PM
Peter Heerma	Officer	May 05 '26	Proposed Sale	46.65	2,174	101,417		May 05 07:31 PM
ROY BAYNES	Director	May 05 '26	Proposed Sale	46.65	4,500	209,925		May 05 04:53 PM
Baynes Roy D.	Director	May 01 '26	Option Exercise	6.82	9,750	66,495	47,250	May 04 04:27 PM
Baynes Roy D.	Director	May 01 '26	Sale	44.22	9,750	431,145	37,500	May 04 04:27 PM
ELIZABETH REED	Officer	May 04 '26	Proposed Sale	45.00	20,000	900,000		May 04 04:04 PM
JEFFREY MECKLER	Director	May 04 '26	Proposed Sale	45.00	8,000	360,000		May 04 04:04 PM
JULA INRIG	Officer	May 04 '26	Proposed Sale	45.00	20,000	900,000		May 04 04:03 PM
ROY BAYNES	Director	May 01 '26	Proposed Sale	44.22	9,750	431,145		May 01 04:15 PM
ROTE WILLIAM E.	Chief Research Officer	Apr 22 '26	Sale	39.09	9,100	355,719	113,987	Apr 23 04:05 PM
ROTE WILLIAM E.	Officer	Apr 22 '26	Proposed Sale	39.09	9,100	355,719		Apr 22 10:36 AM
LYONS GARY A	Director	Apr 14 '26	Option Exercise	16.33	8,000	130,640	65,500	Apr 16 04:05 PM
LYONS GARY A	Director	Apr 14 '26	Sale	41.07	8,000	328,560	57,500	Apr 16 04:05 PM
Baynes Roy D.	Director	Apr 14 '26	Option Exercise	17.60	32,750	576,308	70,250	Apr 16 04:05 PM
Baynes Roy D.	Director	Apr 14 '26	Sale	41.29	32,750	1,352,130	37,500	Apr 16 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Apr 14 '26	Option Exercise	16.05	15,250	244,802	64,330	Apr 16 04:05 PM

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

PresidentDr. Eric M. Dube Ph.D.

Chief Financial OfficerMr. Christopher Cline C.F.A.

Chief Research OfficerDr. William E. Rote Ph.D.

Chief Commercial OfficerMr. Peter Heerma

Executive VPDr. Jula Inrig M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TVTX

Travere Therapeutics Inc

Upgrade your Finviz experience